产品
编 号：F752609
分子式：C25H20ClFN8O
分子量：502.93
分子式：C25H20ClFN8O
分子量：502.93
产品类型
规格
价格
是否有货
结构图
CAS No: 2421122-61-2
产品详情
生物活性：
HDAC-IN-45 (Compound 14) is a small molecule HDAC inhibitor and has anticancer activity, also can forms a hydrogenbond with residue Y303. HDAC-IN-45 (Compound 14) has substantial inhibitory effects towards HDAC1, 2 and 3 isoforms with IC50 values of 0.108, 0.585 and 0.563 μM respectively.
体内研究：
HDAC-IN-45 (Compound 14) (25 mg/kg or 50mg/kg; i.p.; every day) exhibits a potent antitumor efficacy in human MDA-MB-231 breast cancer xenograft mouse model.Animal Model:Human MDA-MB-231 breast cancer xenograft mouse model
Dosage:25 mg/kg or 50mg/kg
Administration:25 mg/kg or 50mg/kg; i.p.; every day.
Result:Exhibited a potent antitumor efficacy.
体外研究：
HDAC-IN-45 (Compound 14) suppresses the growth of triple-negative breast cancer cells MDA-MB-231 (IC50 = 1.48 μM), MDA-MB-468 (IC50= 0.65 μM), and liver cancer cells HepG2 (IC50= 2.44 μM). HDAC-IN-45 has equally virulent in the HDAC-sensitive cell lines (YCC11) and -resistant gastric cell lines (YCC3/7) and overcome HDACi resistance. HDAC-IN-45 has a high toxicity (IC50= 0.33 μM) in three leukemic cell lines, K-562, KG-1 and THP-1. HDAC-IN-45 (Compound 14) has substantial inhibitory effects towards HDAC1, 2 and 3 isoforms with IC50 values of 0.108, 0.585 and 0.563 μM respectively. HDAC-IN-45 (Compound 14) can elevate acetylation level of histone H3 and expression of p21. HDAC-IN-45 (Compound 14) exerts a dose-dependent upregulation of ac-H3K9 in MDA-MB-231 cells, triggers cell cycle arrest in G1 phase. HDAC-IN-45 (Compound 14) exhibits a potent antitumor efficacy in xenograft mouse model.
HDAC-IN-45 (Compound 14) is a small molecule HDAC inhibitor and has anticancer activity, also can forms a hydrogenbond with residue Y303. HDAC-IN-45 (Compound 14) has substantial inhibitory effects towards HDAC1, 2 and 3 isoforms with IC50 values of 0.108, 0.585 and 0.563 μM respectively.
体内研究：
HDAC-IN-45 (Compound 14) (25 mg/kg or 50mg/kg; i.p.; every day) exhibits a potent antitumor efficacy in human MDA-MB-231 breast cancer xenograft mouse model.Animal Model:Human MDA-MB-231 breast cancer xenograft mouse model
Dosage:25 mg/kg or 50mg/kg
Administration:25 mg/kg or 50mg/kg; i.p.; every day.
Result:Exhibited a potent antitumor efficacy.
体外研究：
HDAC-IN-45 (Compound 14) suppresses the growth of triple-negative breast cancer cells MDA-MB-231 (IC50 = 1.48 μM), MDA-MB-468 (IC50= 0.65 μM), and liver cancer cells HepG2 (IC50= 2.44 μM). HDAC-IN-45 has equally virulent in the HDAC-sensitive cell lines (YCC11) and -resistant gastric cell lines (YCC3/7) and overcome HDACi resistance. HDAC-IN-45 has a high toxicity (IC50= 0.33 μM) in three leukemic cell lines, K-562, KG-1 and THP-1. HDAC-IN-45 (Compound 14) has substantial inhibitory effects towards HDAC1, 2 and 3 isoforms with IC50 values of 0.108, 0.585 and 0.563 μM respectively. HDAC-IN-45 (Compound 14) can elevate acetylation level of histone H3 and expression of p21. HDAC-IN-45 (Compound 14) exerts a dose-dependent upregulation of ac-H3K9 in MDA-MB-231 cells, triggers cell cycle arrest in G1 phase. HDAC-IN-45 (Compound 14) exhibits a potent antitumor efficacy in xenograft mouse model.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备